Previous 10 | Next 10 |
2023-03-30 13:33:41 ET RenovoRx ( NASDAQ: RNXT ) entered into a definitive securities purchase agreement with a certain institutional investor for the purchase and sale of 1.56M shares at a purchase price of $3.21/share in a registered direct offering. Offering is exp...
RenovoRx, Inc. (the “Company”) (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of solid tumors, today announced that it has entered into a definitive securities purchase agreement with a certain institutional investor for the purchase and sale of 1,557...
2023-03-30 10:02:34 ET Gainers: SCYNEXIS ( SCYX ) +61% . Palisade Bio ( PALI ) +33% . Biophytis ( BPTS ) +10% . RenovoRx ( RNXT ) +9% . VYNE Therapeutics ( VYNE ) +9% . Losers: AngioDynamics ( ANGO ) -28% . ...
RenovoGem ™ Patients had Greater than 65% Reduction in Side Effects, which can Include Nausea, Fatigue, and Reduced White Blood Cells During Pancreatic Cancer Treatment These Data and Additional Secondary Endpoint Analyses to be Presented at American Association for Cancer Rese...
2023-03-29 12:56:48 ET Gainers: Bird Global ( BRDS ) +44% . Toro Corp ( TORO ) +38% . RenovoRx ( RNXT ) +29% . Arcturus Therapeutics ARCT +26% . Tempest Therapeutics ( TPST ) +26% . Brainstorm Cell Therapeutics ( BCLI ) ...
(NewsDirect) In the interview, Dr. Michael Pishvaian discussed the trial's potential impact on the oncology community as well as how pancreatic cancer patients are treated. Dr. Pishvaian’s interview with OncologyTube is featured here . Recently RenovoRx ( RNXT ) announced...
--News Direct-- In the interview, Dr. Michael Pishvaian discussed the trial's potential impact on the oncology community as well as how pancreatic cancer patients are treated. Dr. Pishvaian’s interview with OncologyTube is featured here . Recently RenovoRx ( RNXT ) announ...
2023-03-08 10:08:08 ET RenovoRx <<RNXT>> announces promising interim data in the Phase III open label TIGeR-PaC clinical trial. The study is investigating the Company’s first product candidate, RenovoGem, as a potential treatment option in locally advanced pancr...
Positive Trend in Median Overall Survival Versus Standard of Care, Warrants Continuation of the Pivotal Trial Full Data Presentation, April 17, 2023, at the 2023 American Association of Cancer Research (AACR) Annual Meeting RenovoRx, Inc. (“RenovoRx” or the...
--News Direct-- Introduction Wouldn’t it be nice if there was a way to increase the doses of chemotherapy to the tumor whilst at the same time reducing the dose for the rest of the body? This would be an ideal way to reduce its horrible side effects? Well, RenovoRx ( RNXT...
News, Short Squeeze, Breakout and More Instantly...
LOS ALTOS, Calif., July 08, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc . (“RenovoRx” or the “Company”) (Nasdaq: RNXT) , a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today annou...
LOS ALTOS, Calif., June 26, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc . (“RenovoRx” or the “Company”) (Nasdaq: RNXT) , a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, announced t...
LOS ALTOS, Calif., June 10, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc . (“RenovoRx” or the “Company”) (Nasdaq: RNXT) , a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, announced t...